<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136150">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01864980</url>
  </required_header>
  <id_info>
    <org_study_id>bleeding SpHb-001</org_study_id>
    <nct_id>NCT01864980</nct_id>
  </id_info>
  <brief_title>Intra-operative Monitoring of Blood Loss</brief_title>
  <official_title>Monitoring of Intraoperative Blood Loss: Benefit of Continuous Noninvasive Haemoglobin Monitoring?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Certain types of surgery are associated with occult blood loss, which is hard to detect
      intraoperatively by intermittent conventional, invasive Hb concentration measurements using
      the clinical standard of Hb monitoring by satellite laboratory analysis (Hbsatlab). The
      investigators want to see whether continuous non-invasive transcutaneous Hb measurement
      using a finger sensor (SpHb), (a) reduces the total time (area under the curve, AUC) a
      patient's Hb is below a predetermined transfusion threshold (HbAUC) for administration of
      red blood cell concentrate (RBC), and (b) prevents a decrease in total oxygen delivery (DO2)
      possibly associated with transfusion below a critical haemoglobin concentration.
      Furthermore, the investigators want to study if SpHb monitoring changes the timing of RBC
      administration and reduces the need for intra- and post-operative RBC transfusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>HbAUC</measure>
    <time_frame>during operation</time_frame>
    <safety_issue>No</safety_issue>
    <description>the total time a patient's Hb is below a predetermined transfusion threshold (HbAUC) for administration of red blood cell concentrate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood transfusions</measure>
    <time_frame>intra- and post operative up to 48h</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number of perioperative blood transfusions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>DO2</measure>
    <time_frame>intraoperative</time_frame>
    <safety_issue>No</safety_issue>
    <description>DO2 = oxygen delivery</description>
  </other_outcome>
  <other_outcome>
    <measure>serum concentrations of high-sensitive troponin T</measure>
    <time_frame>post operative up to 48h</time_frame>
    <safety_issue>No</safety_issue>
    <description>serum concentrations of high-sensitive troponin T</description>
  </other_outcome>
  <other_outcome>
    <measure>serum concentrations of lactate</measure>
    <time_frame>intra- and post operative up to 48h</time_frame>
    <safety_issue>No</safety_issue>
    <description>lactate</description>
  </other_outcome>
  <other_outcome>
    <measure>StO2</measure>
    <time_frame>intraoperative</time_frame>
    <safety_issue>No</safety_issue>
    <description>StO2  = peripheral tissue oxygenation by near-infrared spectroscopy</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Undetected Intraoperative Blood Loss</condition>
  <arm_group>
    <arm_group_label>Hb group:15 patients</arm_group_label>
    <description>scheduled for elective surgery associated with  undetected, i.e., difficult to reliably monitor intraoperative blood loss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SpHb group: 15 patients</arm_group_label>
    <description>scheduled for elective surgery associated with  undetected, i.e., difficult to reliably monitor intraoperative blood loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood transfusion, intermittent Hbsatlab measurement</intervention_name>
    <description>In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)</description>
    <arm_group_label>Hb group:15 patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood transfusion, based on continuous SpHb readings</intervention_name>
    <description>RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.</description>
    <arm_group_label>SpHb group: 15 patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        30 adult patients scheduled for surgery associated with  undetected, i.e., difficult to
        reliably monitor intraoperative blood loss
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at the age of 18 years or older, planned for elective surgery at-risk for
             undetected blood loss.

          -  American Society of Anesthesiologists (ASA) classification I, II, III, IV

        Exclusion Criteria:

          -  Patient refusal

          -  Emergency surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel M.R.F. Struys, Prof.dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of groningen,University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas W.L. Scheeren, Prof.dr/</last_name>
    <email>T.W.L.Scheeren@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rob Spanjersberg</last_name>
    <phone>050-361115/8</phone>
    <phone_ext>0031</phone_ext>
    <email>R.Spanjersberg@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Spanjersberg</last_name>
      <email>r.spanjersberg@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Thomas W.L. Scheeren, Prof.dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>Prof.dr.T.W.L.Scheeren</investigator_full_name>
    <investigator_title>Prof.dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
